Contraceptive Technology Update – August 1, 2024

U.S. Supreme Court’s Decision on Emergency Abortions Raises More Questions than Answers

The big question for OB/GYNs, emergency department (ED) physicians, and the reproductive healthcare community is whether the U.S. Supreme Court’s decision on June 27, 2024, in the case of Idaho and Moyle v. United States, will change emergency care for pregnant women in the United States.

Male Contraceptive Gel Is Most Promising Option in that Arena

Researchers have released positive results from a Phase II study of Nestorone/testosterone (NES/T) transdermal gel, the first male contraception method to progress to Phase II clinical trials.

Combined Oral Contraceptives Can Help Some with Premenstrual Dysphoric Disorder

Reproductive health patients often describe having unpleasant symptoms related to their menstrual cycle. Premenstrual syndrome, for example, refers to any mood symptoms in the days or weeks before their period begins.

Preconception Consult Should Include Advice on Contraception

Separating preconception and contraceptive counseling between OB/GYNs and patients burdens patients and fractures reproductive healthcare. A better solution is to look at pregnancy planning, pregnancy prevention, and risk evaluation holistically.

Opill’s Access Is Great, But Price Is Too Steep for Youth

As Opill, the first over-the-counter (OTC) oral birth control pill to be approved by the Food and Drug Administration (FDA), makes its way to grocery stores and pharmacies across the country, its usefulness remains a question mark for many young people.

Research Shows that Misoprostol Works Well Alone for Medication Abortion

When Americans think of medication abortion, they typically refer to the medication regimen of mifepristone and misoprostol, which together have been shown to be highly effective and safe.